It helps to predict the chance of metastasis for postmenopausal breast cancer patients with the following criteria: ER-positive (and will be treated with hormone therapy), HER2-negative, negative or 1–3 positive lymph nodes, and a tumor size no larger than 5 cm. Here, ERBB2 is linked to breast carcinoma.